BAX vs INVA: fair value comparison
Baxter International Inc. and Innoviva, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, INVA currently sits closer to the top of our discount ranking. INVA carries the stronger quality grade.
| BAX | INVA | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $26.13 | $20.77 |
| 12-month range | $16.78–$28.10 | $18.11–$23.41 |
| Sector rank | #65 of 113 Healthcare | #60 of 113 Healthcare |
| Quality grade | F | B |
| Momentum grade | — | B |
| Leverage | Moderate | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BAX fair value analysis · INVA fair value analysis